However, in our study, the positivity of COX-2 in tumor was as high as 90%, and the number of cases was too small to analyze survival with further stratification between COX-2 and EGFR positive patients. It might be possible that the dual positive expression of COX-2 and EGFR could exert synergistic prognostic and predictive effect on NSCLC survival . Besides, as TKI is becoming the treatment of choice in EGFR gene Capmatinib price mutated advanced NSCLC patients, the role of COX-2 positivity on patient’s
response to TKI might be worthy of further investigation with larger samples. However, it was reported in recently published clinical trials that combined therapy with COX-2 inhibitors and the EGFR inhibitors had no additional benefit in patients who were not responsive to platinum therapy or who were chemotherapy-naive when compared to efficacy reported in previous studies with treatment of EGFR inhibitors alone [41, 42]. Though there was no correlation between EGFR and COX-2 in NSCLC, they might remain as potential, though independent targets for treatment. Conclusions In conclusion, this preliminary study illustrated
that COX-2 and EGFR are both over-expressed in NSCLC. EGFR not only is an independent prognostic factor for overall survival but also a predictive factor for NSCLC receiving radiotherapy. The prognostic value of EGFR and COX-2 AG-120 in vitro co-expression needs further study. Acknowledgements The authors
would like to acknowledge the generous financial support from the Science and Amisulpride Technology Key Project of Sichuan Province, PR. China (Project 03SG022-008 to J.W. and 04SG022-007 to F.X.). References 1. Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 2004, 350:379–392. 2004https://www.selleckchem.com/products/hmpl-504-azd6094-volitinib.html PubMedCrossRef 2. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Põld M, Batra RK, Dubinett : Non-small cell lung cancer cyclooxygenase-2-dependent invasion is mediated by CD44. J Biol Chem 2001, 276:20809–20812.PubMedCrossRef 3. McKay MM, Morrison DK: Integrating signals from RTKs to ERK/MAPK. Oncogene 2007, 26:3113–3121.PubMedCrossRef 4. Schlessinger J: Cell signalling by receptor tyrosine kinases. Cell 2000, 103:211–225.PubMedCrossRef 5. Pold M, Zhu LX, Sharma S, et al.: Cyclooxygenase-2-dependent expression of angiogenic cxc chemokines ena-78/cxc ligand (cxcl) 5 and interleukin-8/cxcl8 in human non-small cell lung cancer. Cancer Res 2004, 64:1850–1860. 6. Choe MS, Zhang X, Shin HJC, Shin DM, Chen Z: Interaction between epidermal growth factor receptor-and cyclooxygenase 2-mediated pathways and its implications for the chemoprevention of head and neck cancer. Mol Cancer Ther 2005,4(9):1448–55. (Georgia)PubMedCrossRef 7. Sahin M, Sahin E, Gümüslü S: Cyclooxygenase-2 in cancer and angiogenesis. Angiology 2009,60(2):242–253.PubMed 8.